Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +91 22-69790010 from 9 AM - 5:30 PM IST

    • Contact
    • Contact

      +91 22-69790010
      from 9 AM - 5:30 PM IST

  • Request More Information
  • Journalists
  • Request More Information
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Request More Information
  • Journalists
  • Request More Information
  • Journalists

India Pharma Survey Reveals Digital Transformation Underway Among Life Sciences Companies in India


News provided by

Veeva Software Systems India Pvt Ltd

28 Apr, 2017, 14:10 IST

Share this article

Share toX

Share this article

Share toX

Veeva Software Systems India Pvt. Ltd. (PRNewsFoto/Veeva Software Systems India)
Veeva Software Systems India Pvt. Ltd. (PRNewsFoto/Veeva Software Systems India)

MUMBAI, April 28, 2017 /PRNewswire/ --

66% of respondents believe digital will become core to company strategy over the next three years

A new industry survey by Veeva Systems reveals that pharmaceutical companies in India will leverage digital as a part of their strategy to achieve greater commercial effectiveness. The Veeva 2016 Digital in Indian Pharma Survey shows a significant shift in customers' expectations to use new digital channels, with 93% focused on increased multichannel interactions and customer engagement (79%).

     (Logo: http://photos.prnewswire.com/prnh/20160816/398387LOGO )

With new opportunities in digital engagement, pharma companies are making digital core to their strategy with multichannel CRM. The lack of a digital strategy is seen as one of the major challenges in adoption, along with organizational readiness. As digital teams work with the business units to understand digital requirements, there is a fragmented view of who should drive this transformation with 21% believing management must lead the way.

"The current approach to digital is incremental in nature and includes processes for e-detailing and field reporting for example. The survey reveals that with a digital strategy in place, technology can enhance the customer relationship management, enable newer engagement models, and improve execution," said Sudhir Kandarth, country manager, Veeva Systems in India.

The Veeva 2016 Digital in Indian Pharma Survey explores the state of digital in the Indian pharmaceutical industry. The report draws on inputs from industry executives across the domains of sales, marketing, sales force and commercial excellence, digital marketing, information technology, and management. The full survey findings are available at http://bit.ly/2m0NQKh .

Additional information

For more on Veeva, visit: veeva.com
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_apac on Twitter: twitter.com/veeva_apac
Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit veeva.com.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-K for the period ended January 31, 2017. This is available on the company's website at veeva.com under the Investors section and on the SEC's website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

Media Contact:
Ruchi Sanganeria
Marketing Manager, Veeva Systems
[email protected]
+91-22-25871612

Modal title

Contact PR Newswire

  • +91 22-69790010

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+91 (0) 22 6169 6000
from 9 AM - 5:30 PM IST
  • Terms of Use
  • Privacy Policy
  • GDPR
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.